ACNR indexed in DOAJ (Directory of Open Access Journals)

DOAJ indexes and promotes quality, peer-reviewed open access journals from around the world. It is the most important community-driven, open access service in the world and has a reputation for advocating best practices and standards in open access. DOAJ’s basic criteria for inclusion have become the accepted way of measuring an open access journal’s adherence to standards…

WFNR celebrates 25th anniversary

“Congratulations to the WFNR for all that it has achieved over the last 25 years.  Today the WFNR is a true advocate for neurorehabilitation” said Professor David Good, WFNR President as the organisation celebrates its 25th anniversary.  He continued: “We’re extremely grateful to all our members who have contributed to the success of the organisation…

Apomorphine Sublingual Film for PD

BIAL announced on 2nd September 2021 that it has entered into an agreement with Sunovion Pharmaceuticals Inc. (Sunovion) whereby BIAL received exclusive commercial license rights to commercialise apomorphine sublingual film in the European Union (EU), the European Economic Area (EEA) and the United Kingdom. Apomorphine sublingual film (APL-130277) is a novel thin film formulation of…

New support group for families affected by brain injury

A new Special Interest Group (SIG) was launched on September 9, 2021 to provide support, advice and resources to families affected by acquired brain injury (ABI). Anchor Point will raise awareness of the needs of families of people with a brain injury, identify their unmet needs and deliver research, information and education required to make…

Ratlas: A new rat brain atlas set to revolutionise neuroscience

The BNA has announced the launch of Ratlas, a new – and freely available – resource that will increase the accuracy and efficiency of experiments and also help to reduce animal numbers used for neuroscience research across the UK.  Ratlas is an atlas of the rat brain that has been developed to revolutionise and support vital…

The Mike Barnes Award for Innovation 2021

Calling all change makers! The Mike Barnes Award for Innovation 2021 recognises and celebrates innovative projects and concepts in the management of Acquired Brain Injury (ABI). It is open to people who may have a project to look at new ways of improving an aspect of neurorehabilitation in hospital, the community, school or prison. You…

MHRA approves PONVORY® (ponesimod) for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis (RMS)

The pivotal Phase 3 OPTIMUM trial showed treatment with ponesimod (n=567) led to a 30.5 percent relative reduction in annual relapse rate (p=0.0003) vs. treatment with teriflunomide (n=566), an active comparator and established first-line oral treatment in adult patients with relapsing multiple sclerosis (RMS)1-4 The OPTIMUM trial is the first head-to-head comparison of two oral…

Istradefylline: CHMP issues negative opinion for in Europe

On 23rd July, Kyowa Kirin Co., Ltd.  announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for istradefylline as an add-on treatment to levodopa (L-Dopa) based regimens in adults living with Parkinson’s, experiencing end-of-dose motor fluctuations. Kyowa Kirin International remain committed to istradefylline and people…

Bial and Medis partnership

13 July 2021: BIAL and Medis, d.o.o. have entered into an exclusive partnership on two of BIAL’s proprietary drugs: Zebinix® (eslicarbazepine acetate) and Ongentys® (opicapone). The established partnership comprises an exclusive distribution agreement for Zebinix® (eslicarbazepine acetate) in the Czech Republic and Slovakia and an exclusive distribution agreement for Ongentys® (opicapone) in 12 CEE countries…